Abstract

Inside Precision MedicineVol. 9, No. 5 InterviewsAsked & Answered – Closing in on Cancer, with PrecisionDamian DohertyDamian DohertyDamian Doherty has been in media and publishing for nearly 30 years, beginning in the early nineties at News Corporation. Damian has managed, edited, and launched life science titles in drug discovery and precision medicine. He was features editor of Drug Discovery World for fourteen years and founded, established, and edited the Journal of Precision Medicine in 2014. In parallel, Damian founded and organized the Precision Medicine Leaders' Summit, a global, immersive 3-day senior leadership conference that still runs today. He edited AIMed magazine in 2019 before launching Photo51Media, a platform for illuminating untold, compelling stories in precision healthcare. Damian joined Mary Ann Liebert in 2021 to help steer the new rebrand and relaunch of Clinical OMICS to Inside Precision Medicine.Search for more papers by this authorPublished Online:22 Oct 2022https://doi.org/10.1089/ipm.09.05.15AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 9Issue 5Oct 2022 InformationCopyright © GEN PublishingTo cite this article:Damian Doherty.Asked & Answered – Closing in on Cancer, with Precision.Inside Precision Medicine.Oct 2022.52-54.http://doi.org/10.1089/ipm.09.05.15Published in Volume: 9 Issue 5: October 22, 2022PDF download

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.